Jon Congleton - Mineralys Therapeutics, CEO Director
| MLYS Stock | 10.24 0.04 0.39% |
CEO
Jon Congleton is CEO Director of Mineralys Therapeutics, Common
| Age | 62 |
| Address | 150 N. Radnor Chester Rd., Radnor, PA, United States, 19087 |
| Phone | 888 378 6240 |
| Web | https://mineralystx.com |
Latest Insider Transactions
Jon Congleton Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jon Congleton against Mineralys Therapeutics, stock is an integral part of due diligence when investing in Mineralys Therapeutics,. Jon Congleton insider activity provides valuable insight into whether Mineralys Therapeutics, is net buyers or sellers over its current business cycle. Note, Mineralys Therapeutics, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Mineralys Therapeutics,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jon Congleton over three months ago Disposition of 15271 shares by Jon Congleton of Mineralys Therapeutics, at 13.518 subject to Rule 16b-3 | ||
Jon Congleton over six months ago Disposition of 15746 shares by Jon Congleton of Mineralys Therapeutics at 13.3415 subject to Rule 16b-3 | ||
Jon Congleton over six months ago Disposition of 14940 shares by Jon Congleton of Mineralys Therapeutics at 11.7294 subject to Rule 16b-3 | ||
Jon Congleton over six months ago Disposition of 16607 shares by Jon Congleton of Mineralys Therapeutics at 11.9873 subject to Rule 16b-3 |
Mineralys Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.5256) % which means that it has lost $0.5256 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8224) %, meaning that it created substantial loss on money invested by shareholders. Mineralys Therapeutics,'s management efficiency ratios could be used to measure how well Mineralys Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.91 in 2025. Return On Capital Employed is likely to drop to -1.06 in 2025. Other Current Assets is likely to gain to about 95.8 M in 2025, whereas Total Assets are likely to drop slightly above 128.6 M in 2025.Similar Executives
| Found 6 records | CEO Age | ||
| Scott Strazik | GE Vernova LLC | 45 | |
| Paolo Pallotti | Enel Chile SA | 57 | |
| J Fletcher | WEC Energy Group | 61 | |
| Scott CPA | WEC Energy Group | 59 | |
| Jamie Welch | Kinetik Holdings | 58 | |
| Brandon Solano | Rave Restaurant Group | 54 | |
Management Performance
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.53 |
Mineralys Therapeutics, Leadership Team
Elected by the shareholders, the Mineralys Therapeutics,'s board of directors comprises two types of representatives: Mineralys Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mineralys. The board's role is to monitor Mineralys Therapeutics,'s management team and ensure that shareholders' interests are well served. Mineralys Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mineralys Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert McKean, Senior CMC | ||
| Adam Levy, CFO Secretary | ||
| Sarah Foster, Vice Resources | ||
| Danielle Bradbury, Senior Assurance | ||
| Jon Congleton, CEO Director | ||
| Cindy Berejikian, Executive Operations | ||
| Minji MBA, Chief Officer | ||
| Jessica Ibbitson, Senior Operations | ||
| Jeffrey Fellows, Senior Affairs | ||
| David MD, Chief Officer | ||
| MD MPH, Founder Chairman |
Mineralys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mineralys Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 312.13 M | ||||
| Shares Outstanding | 49.84 M | ||||
| Shares Owned By Insiders | 2.52 % | ||||
| Shares Owned By Institutions | 97.48 % | ||||
| Number Of Shares Shorted | 1.86 M | ||||
| Price To Book | 2.67 X | ||||
| EBITDA | (192.4 M) | ||||
| Net Income | (177.81 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.